Podcasts about Obesity

Shirin Lafiya Jari Ce tare da Azima Bashir a wannan mako ya mayar da hankali kan wasu alƙaluman mujallar Lancet da ke nuna cewa nan da shekarar 2050 fiye da kashi 50 na yawan al'ummar Afrika musamman Afrika za su zama masu ƙibar da ta wuce ƙima ko kuma Obesity a turance. Alƙaluman na Lancet wanda aka tattara bayan gwaji a ƙasashe fiye da 50 ya nuna cewa matsloli masu alaƙa da cimaka da kuma rashin motsa jiki su ke matsayin kan gaba da za su haddasa wannan matsala ta Obesity ko kuma ƙibar da ta wuce ƙima. Ku latsa alamar sauti don sauraron cikakken shirin.

In this powerful and deeply honest conversation, bariatric surgeon Dr Alex Craven joins The Bari Chronicles to dismantle the myths that continue to shape how obesity is treated — and mistreated — in Australia.From the false belief that people can simply “eat less and move more,” to the idea that metabolic surgery is dangerous, extreme, or a last resort, Dr Craven explains why these narratives are not only wrong, but actively harmful. Drawing on decades of clinical evidence and lived patient experience, he reframes obesity as a complex, biological disease — not a personal failure.This episode explores why effective obesity treatment must protect mental health, preserve a healthy relationship with food, and be offered with the same objectivity as any other life-saving medical therapy. It is a conversation about dignity, evidence, and why listening to lived experience is no longer optional in modern healthcare.

In this interview, Dr.SHIVA Ayyadurai, MIT PhD, Inventor of Email, Scientist, Engineer and Candidate for President, Talks about Green Coffee on Obesity: A Whole Systems Approach

In this eye-opening episode of The Tudor Dixon Podcast, Tudor sits down with author Aimee Donnellan for a deep dive into the meteoric rise of Ozempic—the diabetes drug turned cultural phenomenon for weight loss. Together, they unpack the surprising science behind GLP-1 medications, the growing trend of microdosing, and the real risks users often overlook. Donnellan and Dixon explore how body image pressures, diet culture, and the powerful food industry fuel America’s obesity crisis. They also discuss why the drug has become both celebrated and controversial, and what its popularity means for the future of weight management.See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a myriad of transformative advancements and strategic shifts within these industries, illustrating the profound impact of innovation and regulatory changes on healthcare.Eli Lilly's recent strides in obesity treatment highlight a significant scientific breakthrough with their novel drug, retatrutide. Currently in phase 3 trials, this triple agonist targets GLP-1, GIP, and glucagon receptors, achieving an extraordinary 28.7% weight loss in participants. Additionally, it demonstrated a 75.8% reduction in knee osteoarthritis pain. Yet, the journey to this milestone wasn't without challenges. The trials saw a higher discontinuation rate than earlier studies, reminding us of the delicate balance between efficacy and patient tolerability—a consistent theme in obesity pharmacotherapy as developers strive to maximize benefits while minimizing adverse effects.In a testament to the global nature of drug development, Zealand Pharma has embarked on a $2.5 billion collaboration with a burgeoning Chinese biotech firm. This partnership aims to advance oral cardiometabolic therapies, underscoring the crucial role of strategic alliances in accessing innovative scientific platforms and expanding market reach.Rezolute faced a significant setback with a disappointing phase 3 trial for its hypoglycemia treatment, resulting in an 87% drop in stock value. This starkly illustrates biotech's inherent volatility and the critical importance of robust clinical trial design to mitigate financial risks associated with unsuccessful outcomes.Meanwhile, Moderna is leveraging Nanexa's expertise in long-acting formulations to enhance injectable therapy delivery systems. This collaboration is indicative of a broader industry trend focused on optimizing drug delivery technologies to boost efficacy and patient compliance.Operational restructuring is also evident as Pfizer implements cost-cutting measures, including layoffs in Switzerland, as part of broader strategic initiatives to optimize operations amid rising R&D costs and pricing pressures. Simultaneously, Chris Boulton's transition from Amgen to Prolynx underscores the fluid movement of talent within the industry—a reflection of ongoing strategic realignments.Regulatory landscapes are shifting as well. The FDA's approval of the first non-drug at-home treatment for depression marks an expansion into alternative therapeutic modalities beyond traditional pharmaceuticals. This wearable device offers adults with major depressive disorder a novel treatment option, integrating technology into mental health care—a promising addition to holistic treatment strategies.In another significant regulatory update, Teva Pharmaceuticals agreed to delist numerous patents from the FDA's Orange Book following an FTC ruling. This move is anticipated to foster increased generic competition and potentially lower medication costs for conditions like asthma and diabetes—a critical shift towards greater market accessibility.The FDA has also finalized guidance on promotional materials for biologics and biosimilars, standardizing advertising practices to ensure accurate representation of these products' efficacy and safety profiles amidst an expanding biologics market.Moreover, the FDA has launched its Commissioner's National Priority Voucher Pilot Review Program to expedite critical drug approvals. The first beneficiary under this program was USAntibiotics with Augmentin XR, signaling a potential shift towards more rapid access to essential medications.On the international policy front, recent developments between the UK and US have led to reductions in medicine rebate rates within the UK. This adjustment could lead to increased spending on new medicines, indicating more favorable conditions for pharmaceutical Support the show

SPONSORED In today's episode, sponsored by Royal Canin, we celebrate 20 years of Royal Canin's partnership with the University of Liverpool's Obesity Care Clinic – the world's first specialist weight loss clinic for cats and dogs. This pioneering collaboration has transformed obesity care, combining expert research with exceptional service for clients and referring vet practices. Join us as Georgia Woods-Lee and Professor Alex German share how the Royal Canin Obesity Care Clinic is shaping the future of pet health and the vital role vets can play in tackling obesity. In 2015, Georgia Woods-Lee took the position of clinical lead for the Royal Canin Weight Management Clinic (recently renamed the Royal Canin Obesity Care Clinic) at the University of Liverpool, Small Animal Teaching Hospital, where she is now dealing exclusively with pet obesity care and nutrition. Georgia was awarded her Certificate in Canine and Feline Veterinary Health Nutrition in 2017, the American Veterinary Technician Specialist (VTS) in nutrition certificate in 2019 , and her BSc (Hons) Veterinary Nursing (Top-up) degree in 2022. Georgia is currently working towards a PhD in pet obesity. Alex German holds the position of Royal Canin professor of small animal medicine at the University of Liverpool. He is a 1994 graduate of the University of Bristol and, after spending two years in mixed practice, returned to Bristol to undertake a PhD in mucosal immunology, and then a residency in small animal internal medicine. He is a diplomate of the European College of Veterinary Internal Medicine and also a RCVS-recognised specialist in internal medicine. His clinical and research interests include comparative obesity biology, ageing, preventing chronic disease, gastroenterology, and evidence-based veterinary medicine. For more on the clinic, visit its website at https://www.liverpool.ac.uk/small-animal-teaching-hospital/clinical-services/weight-management/

Think smoking is the only major lifestyle habit shaving years off your life? Think again.

This episode features a large news slate: Federal Reserve's latest interest rate cut, Jobless claims rise the most since early 2020 and New study raises hopes for Lilly's next obesity drug. Roundtable: Tips for beginniers / QOFTWhttps://www.instagram.com/delano.saporu/?hl=en. Connect with me here also: https://newstreetadvisorsgroup.com/social/. Want to support the show? Feel free to do so here! https://anchor.fm/delano-saporu4/support. Thank you for listening.

Episode 1: Obesity as a Chronic Disease Hosted on Acast. See acast.com/privacy for more information.

Listen LIVE weekdays 9am-10am EST on Turf's Up Radio.

Jamie Oliver thinks diet-related illness and growing levels of debt are killing the country he loves. In this frank and open conversation, he tells Amol why we need to go further to help people understand the nutritional value of the food they eat. And although his campaign for the sugar tax brought significant change, Jamie says there is still more to do on school meals, breakfast clubs and food packaging. But Jamie's mission doesn't stop at food. He wants children to be taught how to manage their money and he also sets out a case for reforming education so it better serves children with diverse ways of learning. Reflecting on his own dyslexia, he emphasises the importance of giving every child the support they need to thrive. And following the announcement that Jamie's Italian will return to the UK, Jamie reflects on what went wrong the first time and how he hopes to make the relaunch a success. (00:01:42) Reflecting on the cultural shifts throughout his career (00:06:12) What he thinks of the current state of Britain (00:08:25) Sugar tax (00:11:13) Junk food advertising(00:13:50) What are we getting wrong with obesity? (00:16:58) Decline in cooking (00:19:39) School meals and breakfast club standards (00:23:17) Neurodiversity (00:28:30) How did dyslexia affect him as a child? (00:31:00) Why we need to teach financial literacy to kids (00:35:14) Jamie's radical ideas (00:39:15) The decline of British pubs (00:43:10) Jamie's Italian – why it failed and why he is bringing it back (00:46:55) The ups and downs of fame (00:52:37) Reflecting on his childhood (00:55:52) Amol's reflections GET IN TOUCH * WhatsApp: 0330 123 9480 * Email: radical@bbc.co.uk Episodes of Radical with Amol Rajan are released every Thursday and Your Radical Questions, where you get to put questions to our guests, is released every Monday.Watch on YouTube: https://www.youtube.com/@r4today Watch on BBC iPlayer: https://www.bbc.co.uk/iplayer/episodes/m002f1d0/radical-with-amol-rajan Amol Rajan is a presenter of the Today programme on BBC Radio 4. He is also the host of University Challenge on BBC One. Before that, Amol was media editor at the BBC and editor at The Independent. Radical with Amol Rajan is a Today Podcast. It was made by Lewis Vickers with Anna Budd. Digital production was by Gabriel Purcell-Davis. Technical production was by Mike Regaard. The editor is Sam Bonham. The executive producer is Owenna Griffiths.

Obesity experts believe portion sizes are a key factor in rising obesity rates - and are suggesting smaller meals for smaller people. Professor of Global Health and Nutrition at Auckland University, Boyd Swinburn spoke to Ingrid Hipkiss.

On today's Good Day Health Show - ON DEMAND…Dr. Jack Stockwell, a NUCCA Chiropractor and GAPS Practitioner in SLC, UT (866.867.5070 | ForbiddenDoctor.com | JackStockwell.com), covers the the biggest news in the health and wellness space from a holistic, naturopath perspective. In this episode, Dr. Jack starts with the holiday season and holiday buying. Eating single ingredients (real whole foods) is one of the best things you can do for your body. Avoid ultraprocessed food products, which are always a combination of inflammatory seed oil, sugar, denatured grains, preservatives, and fillers. Then, Dr. Jack discusses Keto products, and something to keep in mind about eggs and natural flavors. One of the least nutritious foods would be breakfast cereals, even “Keto” ones. If you have to, or insist, on having breakfast cereal in your pantry, find one where sugar is not one of the first 3 listed ingredients. Good luck. Just because something is labeled Keto, doesn't mean it's actually healthy. Lastly, Doug and Dr. Jack join together to answer listener questions, including how aspirin's affect developing brains, a link between longterm melatonin use and heart issues, as well as what supplements and nutrients you can add to your over-the-counter (OTC) lineup that will actually help and not cover up issues or cause more issues because they were solely created in a lab and have nothing to do with what nature provides. Website: GoodDayHealthrShow.com Social Media: @GoodDayNetworks

Dr. Hoffman continues his conversation with Dr. Ross Pelton, Director of Science & Education for Essential Formulas Inc., which specializes in premium probiotic products. He's known as the Natural Pharmacist. 

Exploring the Microbiome and Longevity with Dr. Ross Pelton, Director of Science & Education for Essential Formulas Inc., which specializes in premium probiotic products. He's known as the Natural Pharmacist. He details the pivotal role of the gut in chronic disease, referencing the ancient insights of Hippocrates, and explores the concept of postbiotics. The conversation touches on the influence of gut health on various organ systems, the importance of diversity in the gut microbiome, and how lifestyle choices like diet, exercise, and sleep contribute to healthy aging. They also tackle cutting-edge topics such as the implications of GLP-1 medications, anabolic resistance, and the potential benefits of rapamycin for longevity.

Drs. Jack Cush and Artie Kavanaugh preview the upcoming RNL 2026 meeting in Dallas, TX on February 7 & 8, 2026. Register at RheumNow.Live Below is the program: Saturday, February 7, 2026, 7:50 - 8:00 am Welcome & Introductions Drs. Cush and Kavanaugh 8:00 - 10:00 am POD I - Rheumatoid Arthritis: Achieving Better Outcomes 8:00 – 8:30 am Mortality in RA: A Story of Decline, Delay, or Plateau? Elena Myasoedova, MD 8:30 – 9:00 am The Mucosal Hypothesis of Rheumatoid Arthritis Kristen Demoruelle, MD 9:00 – 9:30 am ILD in RA – Recent Advances Jeffrey Sparks, MD 9:30 – 10:00 am Rheumatoid arthritis Faculty Q&A 10:00 - 10:15 am STEP 1: Placebos in Rheumatology Andreas Kerschbaumer, MD 10:15 -10:30 am STEP 2: Disease Modification in Osteoarthritis Tuhina Neogi, MD PhD 10:30 – 11:05 Break 11:05 - 12:10 pm POD II – Advancing Practice 11:05 – 11:30 am Obesity & Inflammation: Weight Management in Rheumatology Uzma Haque, MD 11:30 - 11:55 am Mitigating risk in Rheum Pts undergoing surgery Susan Goodman, MD 11:55 -12:10 pm Practice Panel Faculty Q&A 12:10 – 1:00pm Lunch 1:00 – 3:00 pm POD III – Decisions in Psoriatic Arthritis 1:00 - 1:30 pm Paradoxical Psoriasis and Strange Reactions Joseph Merola, MD 1:30 - 2:00 pm Why Do Plain X rays in Psoriatic Arthritis Arthur Kavanaugh, MD 2:00 - 2:30 pm IL-23 vs IL-17 inhibitors in PsA Andre Ribero, MD 2:30 - 3:00 pm Past, Present & Future of Gout Robert Terkeltaub, MD 3:00 - 3:30 pm Psoriatic Faculty Q&A 3:30 - 4:05 pm Break 4:05 - 4:20 pm STEP 3: Helicobacter Pylori update Byron Cryer, MD 4:20 - 4:35 pm STEP 4: History of Gout Robert Terkeltaub, MD 4:35 – 5:15 pm Keynote Address: 50 Years of Osteoporosis Michael McClung, MD 5:30 – 7:00 pm Reception Sunday, February 8, 2026 Day TOPIC Speaker 7:50-8:00 am Welcome & Introductions Drs. Cush and Kavanaugh 8:00 - 10:00 am POD IV – Staying Ahead of Spondyloarthritis 8:00 – 8:30 am Diagnosing Axial Spondyloarthritis in 2026 Denis Poddubnyy, MD 8:30 – 9:00 am Spondyloarthritis Complications Jessica Walsh, MD 9:00 – 9:30 am 2026 Advances in Spondyloarthritis Catherine Bakewell, MD 9:30 – 10:00 am Spondyloarthritis Faculty Q&A 10:00 – 10:15 am STEP 5: Asymptomatic Elevation of CK Rojit Agarwal, MD MS 10:15 – 10:30 am STEP 6: Update on Myositis Antibodies Rojit Agarwal, MD MS 10:30 – 11:05 am Break 11:05 – 12:10 am POD V – Highlights in Autoimmune Disease 11:05 - 11:35 am SMILE Study – Hydroxychloroquine in ANA+ Arthralgia Nancy Olsen, MD 11:35 – 12:05 am Sjogren's Treatment Landscape in 2026 Matthew Baker, MD 12:05 - 12:20 pm Autoimmune Faculty Q&A 12:20 – 1:25 pm POD VI - Large & Small Vessel Vasculitis 12:20 – 12:45 pm Embracing Relapses in PMR and GCA Michael Putman, MD 12:45 - 1:10 pm Small vessel vasculitis Clay Cockerell, MD 1:10 - 1:25 pm Vasculitis Faculty Q&A 1:30 pm Adjourn

Karl Nadolsky, DO, and W. Timothy Garvey, MD, unpack several key points in the AACE's latest obesity management guidance.

In this episode of Bench to Bedside, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, hosts Dr. Kristy Brown, a nationally recognized expert in cancer metabolism and hormone signaling. Dr. Brown discusses the latest breakthroughs in understanding the relationship between obesity, estrogen, and cancer, along with how these discoveries shape more effective treatments. She reflects on her career and shares moving accounts of patient interactions that fuel her research. The conversation delves into emerging opportunities in cancer treatment and prevention, the role of artificial intelligence in research, and offers advice for early-career scientists on making a meaningful impact. Dr. Brown expresses optimism for future cancer research advancements and the potential for improved patient outcomes. 00:00 Introduction to the Podcast and Today's Topic 00:28 Meet Dr. Kristy Brown: Expert in Cancer Metabolism 01:02 Optimism in Cancer Research: Key Developments 02:31 Proud Moments in Cancer Research 04:15 Obesity, Metabolism, and Cancer: Emerging Discoveries 06:10 Translational Research: From Lab to Clinic 09:08 Advice for Early Career Scientists 12:18 Hope for the Future: Personal Reflections 13:24 Conclusion and Resources Links from this Episode: ·       Learn more about Dr. Kristy Brown ·       Learn about Dr. Brown's research ·       Learn about cancer prevention at KU Cancer Center To ensure you get our latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center.

Get an extra 4 months of ExpressVPN for free: go to https://www.expressvpn.com/official Get 25% off Fitbod or try the app for FREE: go to https://www.fitbod.me/official Get additional episodes and bonus content with early access (try now with 7 DAYS FREE): go to https://www.OFFICIAL.men Three close man friends gather to talk about spice. This is the Official Podcast. Every Tuesday. Links Below. THE OFFICIAL NETWORK CHANNEL (SUBSCRIBE NOW): https://www.youtube.com/channel/UCcHYe-Qw7qUN5gFWMdj9nNw Episode 467: Recorded 03/12/25 --- Get additional episodes and bonus content with early access: Go to https://www.OFFICIAL.men or https://www.PATREON.com/THEOFFICIALPODCAST --- Timestamps: [00:00:31] Introduction and missing hosts jokes [00:03:11] Kaya Had a Friendsgiving [00:09:44] Flavortown & Pepper Palace [00:32:27] Sexism vs. misogyny [00:42:12] Obesity in American culture [01:00:15] The train graveyard [01:04:51] Wrap --- Audio Platforms (Spotify, Apple, Amazon & Castbox): https://linktr.ee/theofficialpodcast Other Shows: https://linktr.ee/theofficialnetwork --- Hosts: Jackson: https://twitter.com/zealotonpc Andrew: https://twitter.com/huggbeestv Kaya: https://twitter.com/kayaorsan --- Additional Links: Channel: https://www.youtube.com/channel/UCcHYe-Qw7qUN5gFWMdj9nNw SubReddit: https://reddit.com/r/theofficialpodcast Patreon: https://www.patreon.com/theofficialpodcast Intro by: https://www.youtube.com/c/Derpmii Music by: https://soundcloud.com/inst1nctive & https://www.instagram.com/00zaya Art by: https://www.instagram.com/nook_eilyk/ & https://www.instagram.com/vaux.z Edited by: https://www.instagram.com/00zaya Designer: http://www.jr-design-co.com/ Produced by Jackson Clarke for The Official Network Learn more about your ad choices. Visit megaphone.fm/adchoices

Nearly 70% of U.S. adults now qualify as obese under a new definition that goes beyond body mass index (BMI) to include waist and hip measurements, exposing millions with hidden fat linked to higher disease risk The new standard, developed by an international panel and endorsed by dozens of medical organizations, identifies both clinical obesity — where fat is already harming organs — and preclinical obesity, where fat-driven dysfunction is just beginning Using the expanded criteria, researchers found a 60% surge in obesity prevalence, revealing that about 1 in 4 adults were reclassified as obese — mostly from the overweight group — while roughly 1 in 17 with a "normal" BMI carried hidden visceral fat that raises the risk for diabetes, heart disease, and early death BMI alone fails to distinguish between fat and muscle or between safe subcutaneous fat and harmful visceral fat, meaning many healthy people are misclassified while those at real metabolic risk go undiagnosed Measuring your waist-to-hip or waist-to-height ratio provides a far clearer picture of your metabolic health, empowering you to take early action — through healthy eating, reduced toxin exposure, and daily movement — to restore energy and prevent chronic disease

This week we are talking about Pancreatic cancer.  This is a type of cancer that begins as a growth of cells in the pancreas. The pancreas lies behind the lower part of the stomach. It makes enzymes that help digest food and hormones that help manage blood sugar. The most common type of pancreatic cancer is pancreatic ductal adenocarcinoma. This type begins in the cells that line the ducts that carry digestive enzymes out of the pancreas. Pancreatic cancer rarely is found at its early stages when the chance of curing it is greatest. This is because it often doesn't cause symptoms until after it has spread to other organs. Your health care team considers the extent of your pancreatic cancer when creating your treatment plan. Treatment options may include surgery, chemotherapy, radiation therapy or a mix of these. Pancreatic cancer often doesn't cause symptoms until the disease is advanced. When they happen, signs and symptoms of pancreatic cancer may include: Belly pain that spreads to the sides or back. Loss of appetite. Weight loss. Yellowing of the skin and the whites of the eyes, called jaundice. Light-colored or floating stools. Dark-colored urine. Itching. New diagnosis of diabetes or diabetes that's getting harder to control. Pain and swelling in an arm or leg, which might be caused by a blood clot. Tiredness or weakness. It's not clear what causes pancreatic cancer. Doctors have found some factors that might raise the risk of this type of cancer. These include smoking and having a family history of pancreatic cancer. Understanding the pancreas The pancreas is about 6 inches (15 centimeters) long and looks something like a pear lying on its side. It releases hormones, including insulin. These hormones help the body process the sugar in the foods you eat. The pancreas also makes digestive juices to help the body digest food and take in nutrients. How pancreatic cancer forms Pancreatic cancer happens when cells in the pancreas develop changes in their DNA. A cell's DNA holds the instructions that tell a cell what to do. In healthy cells, the instructions tell the cells to grow and multiply at a set rate. The cells die at a set time. In cancer cells, the changes give different instructions. The changes tell the cancer cells to make many more cells quickly. Cancer cells can keep living when healthy cells would die. This causes there to be too many cells. The cancer cells might form a mass called a tumor. The tumor can grow to invade and destroy healthy body tissue. In time, cancer cells can break away and spread to other parts of the body. Most pancreatic cancer begins in the cells that line the ducts of the pancreas. This type of cancer is called pancreatic ductal adenocarcinoma or pancreatic exocrine cancer. Less often, cancer can form in the hormone-producing cells or the neuroendocrine cells of the pancreas. These types of cancer are called pancreatic neuroendocrine tumors or pancreatic endocrine cancer. Risk factors Factors that might raise the risk of pancreatic cancer include: Smoking. Type 2 diabetes. Chronic inflammation of the pancreas, called pancreatitis. Family history of DNA changes that can increase cancer risk. These include changes in the BRCA2 gene, Lynch syndrome and familial atypical multiple mole melanoma (FAMMM) syndrome. Family history of pancreatic cancer. Obesity. Older age. Most people with pancreatic cancer are over 65. Drinking a lot of alcohol. As pancreatic cancer progresses, it can cause complications such as: Weight loss. People with pancreatic cancer might lose weight as the cancer uses more of the body's energy. Nausea and vomiting caused by cancer treatments or a cancer pressing on the stomach might make it hard to eat. Sometimes the body has trouble getting nutrients from food because the pancreas isn't making enough digestive juices. Jaundice. Pancreatic cancer that blocks the liver's bile duct can cause jaundice. Signs include yellowing of the skin and the whites of the eyes. Jaundice can cause dark-colored urine and pale-colored stools. Jaundice often occurs without belly pain. If the bile duct is blocked, a plastic or metal tube called a stent can be put inside it. The stent helps hold the bile duct open. This is done using a procedure called endoscopic retrograde cholangiopancreatography, also called ERCP. During ERCP, a health care professional puts a long tube with a tiny camera, called an endoscope, down the throat. The tube goes through the stomach and into the upper part of the small intestine. The health professional puts a dye into the pancreatic ducts and bile ducts through a small tube that fits through the endoscope. The dye helps the ducts show up on imaging tests. The health professional uses those images to place a stent at the right spot in the duct to help hold it open. Pain. A growing tumor may press on nerves in your abdomen, causing pain that can become severe. Pain medications can help you feel more comfortable. Treatments, such as radiation and chemotherapy, might help slow tumor growth and provide some pain relief. When medicines aren't helping, a health care professional might suggest a celiac plexus block. This procedure uses a needle to put alcohol into the nerves that control pain in the belly. The alcohol stops the nerves from sending pain signals to the brain. Bowel blockage. Pancreatic cancer can grow into or press on the first part of the small intestine, called the duodenum. This can block the flow of digested food from the stomach into the intestines. A health care professional might suggest putting a tube called a stent in the small intestine to hold it open. Sometimes, it might help to have surgery to place a feeding tube. Or surgery can attach the stomach to a lower part of the intestines where the cancer isn't causing a blockage. Prevention Screening for people with a high risk of pancreatic cancer Screening uses tests to look for signs of pancreatic cancer in people who don't have symptoms. It might be an option if you have a very high risk of pancreatic cancer. Your risk might be high if you have a strong family history of pancreatic cancer or if you have an inherited DNA change that increases the risk of cancer. Pancreatic cancer screening might involve imaging tests, such as MRI and ultrasound. These tests are generally repeated every year. The goal of screening is to find pancreatic cancer when it's small and most likely to be cured. Research is ongoing, so it's not yet clear whether screening can lower the risk of dying of pancreatic cancer. There are risks to screening. This includes the chance of finding something that requires surgery but later turns out to not be cancer. Talk about the benefits and risks of pancreatic cancer screening with your health care team. Together you can decide whether screening is right for you. Genetic testing for cancer risk If you have a family history of pancreatic cancer, discuss it with a health care professional. The health professional can review your family history and help you understand whether genetic testing might be right for you. Genetic testing can find DNA changes that run in families and increase the risk of cancer. If you're interested in genetic testing, you might be referred to a genetic counselor or other health care professional trained in genetics. Ways to lower risk You might reduce your risk of pancreatic cancer if you: Stop smoking. If you smoke, talk to a member of your health care team about ways to help you stop. These might include support groups, medicines and nicotine replacement therapy. Maintain a healthy weight. If you are at a healthy weight, work to maintain it. If you need to lose weight, aim for a slow, steady weight loss of 1 to 2 pounds (0.5 to 1 kilogram) a week. To help you lose weight, exercise most days of the week. Slowly increase the amount of exercise you get. Choose a diet rich in vegetables, fruit and whole grains with smaller portions.  (CREDITS: MAYO CLINIC)

Episode Timeline & Main Topics 00:00 — Opening & Community Update • First week doing the podcast fully live thanks to the On The Pen community • Overview of why this week's news is a major turning point in obesity medicine 02:30 — Introducing the “One-and-Done” Obesity Drug (Wave Life Sciences) • WVE-007 early data drops • Why this therapy is unlike GLP-1s or any nutrient-stimulated hormone • Fat loss results and lean-mass increase 06:30 — How Wave-007 Works: INHBE Gene Silencing • Mechanism behind visceral fat reduction • Why this shifts the field toward “quality of weight loss” 09:15 — Why Lean-Mass Preservation Matters • Current GLP-1 medications and muscle loss • Why women dominate trial enrollment and the larger implications • Medicare patients and the coming wave of GLP-1 coverage 13:45 — The Future of Maintenance Therapies • Fractyl Health Revita results • Lilly's orforglipron maintenance design • Why “holding the line” after GLP-1 therapy is the next major category 17:30 — Amylin Agonists: Cagrelintide vs. Eloralintide • Novo's delays and the strategy behind them • Lilly's surprising phase 2 results (up to 20% weight loss) • Combination therapies with tirzepatide or retatrutide 22:30 — FDA Pipeline Acceleration • Potential removal of traditional phase 3 trials • How this speeds up the arrival of next-generation therapies 24:15 — Oral GLP-1 Small Molecules (Structure Therapeutics) • Alaniglipron data and the stock surge • Comparisons to orforglipron and past failures like denuglipron • Why Dave remains skeptical 28:40 — Sponsor Break: Shed & Shapa • Access, coaching, and patient support • Using a numberless scale to build a healthier relationship with weight tracking 31:10 — Counterfeit Ozempic Warning • New fake lot discovered in U.S. pharmacies • How to identify counterfeit pens • Why this should be a national headline • The broader question of drug supply-chain vulnerability 36:00 — Closing Thoughts on the Future of Obesity Medicine • Moving from “more weight loss” to “better weight loss” • Why the field is closer than ever to reshaping obesity as a disease • Gratitude for the community making full-time coverage possible Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Therese Markow and Dr. Robert Klitzman discuss the implications of new anti-obesity drugs, initially designed for type 2 diabetes but now used for weight loss. These drugs are expensive and may not be fully covered by insurance. They discuss how the drugs work and explain why they may be more effective for some than others. Dr. Klitzman highlights the socio-economic disparity that contributes to some of the causes of obesity. He emphasizes the need for prevention and policy changes to address the root causes of obesity, including dietary habits and access to healthy food.   Key Takeaways: The US spends twice as much per person on health care as any other country in the world, yet our health indices are nowhere near the top. A lot of that is because of the price of drugs. Obesity medications are being touted as the end of the obesity pandemic, as a cure-all. However, while they do a lot of good, there are many limitations to the drugs.  Obesity is often more prevalent in lower socio-economic classes. With the increased use of these obesity drugs, the disparity between the haves and have-nots will continue to grow, potentially leading to additional stigmas being placed on those struggling with obesity.   "I do have concerns that the attention on drugs, if we're going to spend a lot of money on drugs for obesity, my concern is we're not going to spend as much attention on how to prevent obesity in the first place." —  Dr. Robert Klitzman   Connect with Dr. Robert Klitzman: Professional Bio: https://www.publichealth.columbia.edu/profile/robert-klitzman-md  Website: https://sps.columbia.edu/person/robert-klitzman-md  LinkedIn: https://www.linkedin.com/in/robert-klitzman/    Connect with Therese: Website: www.criticallyspeaking.net Threads: @critically_speaking Email: theresemarkow@criticallyspeaking.net    Audio production by Turnkey Podcast Productions. You're the expert. Your podcast will prove it. 

161. The Overlap between Binge Eating Disorder and Obesity (Part 2) In this episode, I'm breaking down the difference between Binge Eating Disorder (BED) and the emotional or hedonic eating patterns we often see in obesity. While BED and obesity can overlap, they're not the same — and treatment looks very different for each. I share who to screen for BED, how to ask about eating behaviours with compassion, and the most effective treatment options, including CBT-ED, nutrition therapy, and medications. Then I shift into understanding non-BED overeating patterns driven by emotional eating, all-or-nothing thinking, and over-desire around food. If you want a clearer, more compassionate understanding of eating disorders and obesity-related eating behaviours, this episode will guide you through both. WORK WITH ME Recover Strong CBT-ED program for Binge Eatinghttps://www.sashahighmd.com/bed O​​ntario-Wide Virtual Obesity Management Clinichttps://www.highmetabolicclinic.com Join my Lifestyle Coaching Program for women, Best Weighthttps://www.sashahighmd.com/bestweight Taking the first step toward weight loss can feel overwhelming — but you don't have to do it alone. I've created a curated list of my podcast episodes to gently guide you as you begin your journey. https://www.sashahighmd.com/podcast-guide

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and challenges that are shaping this dynamic industry.Pfizer has recently unveiled phase 3 results for its hemophilia drug Hympavzi, positioning it as a formidable competitor against Sanofi's Qfitlia and Novo Nordisk's Alhemo. The data suggests Hympavzi offers robust efficacy, potentially revolutionizing hemophilia treatment and enhancing patient outcomes significantly. This development is not just about competition; it represents a critical stride forward in patient care for those affected by this debilitating condition.UCB plans to seek regulatory approval for Fintepla to treat an additional epileptic disorder following positive phase 3 trial results in patients with CDKL5 deficiency disorder. This decision reflects promising results and could offer new hope to patients with limited treatment options, further cementing Fintepla's position in epilepsy management.Gene therapy continues to shine with CSL's Hemgenix demonstrating sustained long-term benefits. After five years of follow-up, a single dose has reduced annualized bleeding rates by an impressive 90% in hemophilia B patients within the Hope-B study. Such long-term efficacy highlights gene therapy's transformative potential, offering lasting improvements in quality of life for patients with genetic disorders.Regulatory frameworks are also evolving, as evidenced by the CDC's Advisory Committee on Immunization Practices (ACIP) voting to modify hepatitis B vaccine guidance for newborns. This decision advocates an individualized approach, sparking debate over vaccination strategies, which reflects the complexities and delicate balance required in public health policies today.Regeneron is making strides to simplify treatment regimens for T-cell engagers Lynozyfic and Ordspono. By reducing regimen complexity, they aim to improve patient compliance and expand access, thus enhancing the potential impact on cancer care—a crucial step toward broader therapeutic accessibility.In an effort to address cost barriers and stimulate domestic production of generics, Mark Cuban has proposed lowering FDA fees. This proposal highlights ongoing discussions around regulatory reforms needed to boost generics manufacturing in the United States. Such initiatives align with broader industry goals of increasing access to affordable medications.Despite these advancements, industry insiders have expressed concerns about "unprecedented turmoil" within the FDA. These challenges underscore the critical role of stable leadership in maintaining public trust and ensuring effective regulation amidst rapid scientific progress.Obesity treatments are gaining significant attention as companies like Wave Life Sciences and Structure Therapeutics report promising data, capturing increased investor interest. This trend underscores a growing focus on innovative pharmacological approaches to address obesity—a complex, multifactorial condition that affects millions globally.The strategic landscape of cancer diagnostics is also evolving, as evidenced by Natera's acquisition of Foresight Diagnostics. This deal underscores ongoing industry consolidation efforts aimed at enhancing technological capabilities and expanding market presence—a testament to the critical role diagnostics play in comprehensive cancer care strategies.As we observe these developments, it's clear that scientific innovation coupled with strategic regulatory maneuvers is shaping the future of healthcare. These advancements offer profound implications for patient care, providing new hope through advanced therapies while highlighting the importance of effective regulation and strategic partnerships.Precision medicine continues to extend beyond oncology into fields like cardiometabolic and neSupport the show

On today's Good Day Health Show - ON DEMAND…Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health. First up, Doug and Dr. Ken discuss the biggest news stories in the medical world, starting with a discussion on a new treatment for Hereditary Hemorrhagic Telangiectasia (HHT), which is good news for people who suffer from this rare mality, the a proof of concept trial for a new oral therapy for those who deal with severe and recurrent nose bleeds and internal bleeding. In the past, there was no treatment for this, so this is great news and a wonderful step forward for those with HHT. Next up, in Respiratory Syncytial Virus (RSV) news, preventative measures are being tested so that newborns, who are most susceptible, will have a better chance at prevention of acute lung conditions as well as lifelong lung condition of asthma. RSV immunizations can help prevent future children from developing asthma. Then, Doug and Dr. Ken discuss new guidelines for obesity drugs around the world with the World Health Organization (WHO) releasing global guidelines on GLP-1s with key recommendations warning that the medications should not be a stand alone solution. Weight loss drugs should be incorporated into a comprehensive care plan that includes diet and physical activity. WHO also goes into highlighting concerns of global equity, cost and longterm data gaps. The conversation shifts to a study on “beer bellies,” and what it means for heart health and risks, especially in men. Belly fat seems to be linked to changes in heart structure that contribute to heart failure. The heart muscle itself thickens without the heart itself increasing in size, which leads to a smaller volume of blood able to be pumped out of the heart. Another item of obesity has to do with youngsters and the correlation of pre-teens spending too much Tim eon their phones, leading to less time spent with physical activity. This leads to increased risk of depression, obesity, and lower sleep qualities. Other news includes a new treatment for spinal problems, the FDA's granted accelerated approval for a drug treatment for adults with primary IgA Nephropathy, a study on fame being a killer, whether or not shoulder surgery benefits outweigh the risks involved, and new conclusions of a link between acetaminophen (Tylenol being the most famous brand) and whether or not it's causing autism or ADHD in children when the mother used the drug during pregnancy.  Website: GoodDayHealthrShow.com Social Media: @GoodDayNetworks

Revolutionary study highlights anti-aging benefits of collagen supplementation; Creatine gummies flunk potency tests; Do small irregularities on an endoscopy dictate a lifetime prescription for acid-blockers? How exercise slows cancer and forestalls dementia; Pregnant women require frequent thyroid checks to avert autism; Fructose may stoke body-wide inflammation; What causes bleeding gums? 

First shots fired in war against ultra-processed foods; What the big reveal of Trump's MRI really shows; Is cruelty to horses really necessary to make estrogen? Early smartphone use linked to mental harms in kids; Nutritionist sues American Diabetes Association for forcing her to promote unhealthy artificial sweeteners; Halle Berry dings California Governor Newsom for vetoing menopause awareness bill.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions about BMI cutoffs, weight cycling, metabolic adaptation, trauma, GLP-1 differences, and why some people gain weight on ultra-low calories. Dr. Cooper explains what's really happening inside the metabolic system and why individualized treatment—not dieting—creates sustainable change.Key Questions AnsweredIf my BMI doesn't “qualify” for GLP-1s, is Naltrexone + Bupropion helpful—and what labs matter first?Does being overweight always indicate metabolic dysfunction, and why are U.S. rates so high?If diets damage metabolism, what do you do when you're already 80 pounds overweight?How long does it take for leptin and ghrelin to stabilize with mechanical eating?How can someone gain weight on 1,200 calories/day?After sleeve gastrectomy, how do you eat enough while on a GLP-1?Is set point theory real—and how does the melanocortin pathway influence it?If obesity runs in my family, will I need meds like Zepbound for life?How do trauma and stress alter long-term metabolic health?Can GLP-1s offset weight gain from steroids, mood meds, or hormones?Why might Ozempic work well while Mounjaro causes weight gain?Key Takeaways1. BMI rules don't reflect metabolic truth.A mid-20s BMI can still mask significant dysfunction, especially with weight cycling.2. Weight cycling is metabolically stressful.Repeated losses/regains increase visceral fat, insulin abnormalities, and cardiovascular risk.3. Obesity is a multi-hormonal disease.Most people need pharmacology plus sleep, fueling, and movement—not restrictive dieting.4. Metabolic adaptation is powerful.Under-fueling lowers thyroid output, suppresses fat-burning, and slows metabolism dramatically.5. After bariatric surgery or on GLP-1s, frequency matters.Frequent, nutrient-dense snacks protect muscle, metabolism, and energy.6. Set point changes with better signaling.GLP-1s and related therapies help the brain accurately detect weight and lower the defended level.7. Genetics often mean lifelong support.Family patterns of obesity usually indicate long-term need for metabolic medication.8. Trauma amplifies metabolic risk.Childhood trauma disrupts IGF-1, sleep, stress hormones, insulin, leptin, and ghrelin.9. Medications can cause weight gain—GLP-1s can help counteract it.Steroids, mood meds, hormonal agents, and more can be metabolically unfriendly.10. “Newer” isn't always better.Some people respond poorly to the GIP component in Mounjaro/Zepbound. Individual physiology rules.Dr. Cooper's Actionable TipsRequest deeper evaluation: DEXA, visceral fat, fasting insulin/glucose, leptin, reproductive hormones.Stop restrictive dieting permanently—mechanical eating protects metabolic stability.Work with a fueling-focused dietitian (often ED-trained).Review your medication list for drugs known to cause weight gain.Don't switch GLP-1s or chase higher doses if your current regimen works.Notable Quote“Obesity isn't a willpower problem. It's a metabolic disease, and when the underlying system is supported, the body finally has permission to change.” — Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

Send us a message with this link, we would love to hear from you. Standard message rates may apply.We share a quick life update, welcome our first guest Mike Rozanski, and clear up the Michelin Guide origin story before shifting to a focused guide on starting GLP-1 medications. Practical strategies cover injections, nausea, constipation, muscle protection, and adjusting other meds safely.• board certification in obesity medicine and motivation to destigmatise care• guest segment on Michelin guide history and Philly's recent stars• what GLP-1 meds are and how auto-injectors work• portion sizing to prevent nausea and early side effects• fiber with fluids to prevent constipation• protein targets and simple strength training to protect muscle• when to adjust blood pressure and diabetes medications• key takeaways and encouragement to start small and follow upIf you found this helpful, a review really does go a long way for a like on whatever app you're listening to us onSupport the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

If you're over 60 and using GLP-1 medications like Wegovy or Zepbound, this episode could save your independence. In this episode, I reveal the hidden danger of rapid weight loss without muscle protection—and the simple strategies that keep you strong, steady, and mobile as the pounds come off. GLP-1 medications are transforming weight loss for older adults managing diabetes, high blood pressure, and joint pain. But there's a critical piece most people miss: sarcopenia. This age-related muscle loss accelerates during weight loss, putting you at risk for falls, fractures, and losing the strength you need for daily activities. Tune in to learn how to lose weight safely while protecting the muscle that keeps you independent—and why strength training, protein intake, and staying active aren't optional on this journey.   Episode Highlights: Why GLP-1 medications like Wegovy and Zepbound are game-changers for adults 60+ The connection between muscle loss, falls, fractures, and loss of independence How sarcopenia affects metabolism, blood sugar control, and bone health Protein requirements for older adults (25-30 grams per meal) Simple strength training routines you can do at home—no gym required Red flags that muscle loss is happening too fast Real patient story: turning weakness into strength on a GLP-1 journey   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Should restaurants serve smaller portion sizes to women because they need less calories?According to the head of the UK Government's obesity programme, menus should be adapted to include smaller versions of meals that contain fewer calories, as part of an effort to drive down obesity rates.What do you think?Joining guest host Anna Daly to discuss is Professor Naveed Sattar, Professor of Metabolic Medicine at the University of Glasgow, Professor Donal O'Shea, HSE Clinical Lead for Obesity and listeners.

Hollywood's Headlines includes the 76ers getting fined for false injury reporting, a UCLA study finds that a healthy marriage may lower your risk of obesity, and collectors are scrambling as a Larry Bird jersey and his debut game tickets head to auction.

Pediatrician and mom, Dr. Chrissie Ott, chats about the use of GLP-1 meds in kids and teens.

With the prospect of American Ozempic-style drugs coming on the market for dogs and cats, just how big a problem is pet obesity in Ireland?Joining Seán to discuss is Pete Wedderburn, aka Pete the Vet…

This episode covers: Cardiology This Week: A concise summary of recent studies DAPT: how short is too short Obesity and atrial fibrillation Milestones: COURAGE  Host: Emer Joyce Guests: Carlos Aguiar, Steffen Massberg, Prash Sanders Want to watch that episode? Go to: https://esc365.escardio.org/event/2178 Want to watch that extended interview on dual antiplatelet therapy (DAPT) and shortening its optimal duration, go to: https://esc365.escardio.org/event/2178?resource=interview   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Emer Joyce, Nicolle Kraenkel and Steffen Massberg have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Prashanthan Sanders has declared to have potential conflicts of interest to report: advisory board representative University of Adelaide, Medtronic, Boston Scientific, CathRx, Abbott and Pacemate as well as research grants for University of Adelaide: Medtronic, Abbott, Boston Scientific, Becton Dickson. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

The number of people using injectable obesity treatments is growing. Will Americans' access continue to increase?

GLP-1 medications are changing the game in obesity care. Patients are losing weight, feeling full faster… and often eating less overall. But less food can also mean less muscle, unless we guide them toward the right nutrition.  In today's episode, we unpack how clinicians can better counsel patients using anti-obesity meds, and how nutrient-dense, affordable options like pork can support satiety, muscle maintenance, and sustainable weight loss. In this episode, we cover: How GLP-1 medications affect hunger, fullness, and food preference What makes a protein “high quality” — and why that matters for preserving lean mass How pork compares to other proteins like chicken, tofu, and beef when it comes to: Nutrients like vitamin B12, selenium, iron, and thiamin Satiety and fullness Affordability and accessibility How to assess whether a patient is meeting protein needs — even with a reduced appetite The “Pork + Plants” strategy and why pairing protein with fiber supports GLP-1 success This episode is brought to you by the National Pork Board's Pork & Partners healthcare professional community, helping clinicians reframe the role of lean pork in a healthy diet. You can join here!  Resources Mentioned: Episode 109: Is Pork More Nutritious Than You Think Lean Pork GuidePork Comparison GuideRole of Pork for Patient's Using GLP-1sAny Questions? Send Me a MessageSupport the showConnect with Colleen:InstagramLinkedInSign up for my FREE Newsletter - Nutrition hot-topics delivered to your inbox each week. Disclaimer: This podcast is a collection of ideas, strategies, and opinions of the author(s). Its goal is to provide useful information on each of the topics shared within. It is not intended to provide medical, health, or professional consultation or to diagnosis-specific weight or feeding challenges. The author(s) advises the reader to always consult with appropriate health, medical, and professional consultants for support for individual children and family situations. The author(s) do not take responsibility for the personal or other risks, loss, or liability incurred as a direct or indirect consequence of the application or use of information provided. All opinions stated in this podcast are my own and do not reflect the opinions of my employer.

Technically known as glucagon-like peptide-1 receptor agonists, or GLP-1, these drugs have been around for years for treating diabetes. Now it seems most people think of GLP-1 drugs as medications to lose weight, and these medications are so popular that for a time, supply could not meet demand, leaving many to seek compounded GLP-1 medications, which were more accessible and affordable. However, compounded medications are not FDA-approved, and there are questions regarding their safety and efficacy. What do doctors and patients need to know when considering using compounded obesity medications? To help answer this, host Aaron Lohr talks with Michael Weintraub, MD, an endocrinologist at NYU Langone Division of Endocrinology. Dr. Weintraub serves on the exam writing committee for the American Board of Obesity Medicine. Support for this episode was provided by Lilly. Show notes are available at https://www.endocrine.org/podcast/enp107 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Obesity increases Alzheimer's risk by altering how fat-derived vesicles communicate with the brain, causing amyloid proteins to misfold and form toxic plaques that damage neurons and impair cognition Specific lipids from obese individuals, including sphingolipids and ceramides, create oxidative stress in brain cells, reduce mitochondrial energy production, and accelerate the formation of sticky amyloid aggregates Excessive fat consumption promotes Alzheimer's development, though balanced, controlled intake at lower concentrations helps inhibit amyloid aggregation and reduce disease risk Leptin resistance from obesity prevents this protective hormone from reaching the brain, disabling the cleanup process that normally breaks down amyloid proteins while worsening inflammation and cognitive decline Cellular health restoration requires eliminating four key factors — excess linoleic acid from vegetable oils, endocrine-disrupting chemicals, electromagnetic fields, and endotoxins in the gut

We discuss the risk factors for infant obesity and the prevention strategies to be studied.

The New Tax Law: IRS Must Show You Your Mistakes Trouble in Toyland! Dangers of AI Toys Iron County School District considers four-day school week Combatting Math Anxiety Utah Women Run hosts Martha Hughes Cannon Awards Ceremony Over 50 Dead Roosters: Cockfighting Ring Discovered in Provo Asylum Decisions on Pause: Afghan Amnesty Halted and a New Travel Ban? Afghan Refugees in Utah: Fear Amid Federal Crackdown Giving Tuesday: One Kind Act A Day

The holidays are usually when you ask Santa for the latest gadgets and gizmos, but if a smartphone is on the list for your tween, you may want to reconsider. A new study published in the journal Pediatrics shows that Kids who have smartphones by age 12 have a higher risk of depression and obesity.  We discuss the study's findings and ask Utahns at what age it is right to give your kid a smartphone.  

If you've ever laid in bed wired, exhausted, and dreading tomorrow's alarm, this episode is your playbook on how to improve sleep quality as a man who actually has things to do. In this no‑BS conversation, we dig into how to improve sleep quality so you can boost recovery, calm your mind, and stop feeling like you're running on fumes. You'll hear how to improve sleep quality using simple, repeatable habits instead of gimmicks, and why better sleep might be the most powerful “performance enhancer” you're not truly using yet.Sleep is way more than closing your eyes; it's your nightly reset for testosterone, mood, focus, and emotional resilience, and guys who short-change sleep pay for it with anxiety, irritability, weaker gains, and a higher risk of burnout and health issues. That's why this episode with Sleep Genius founder and former Navy SEAL Robert Sweetman goes deep on practical sleep hygiene, stress management, and recovery tactics designed for high-performing men who still want to show up strong for their families, teams, and missions.You'll learn how to lock in a consistent sleep schedule without feeling like a monk, how to set up a “sleep cave” that's dark, cool, and distraction‑free, and how to use light, timing, and movement during the day so your brain actually wants to shut down at night. Rob unpacks battle-tested tools from elite environments—like deliberate wind‑down routines, mental off‑loading, breathing, and mindfulness—to help calm your mind before bed so you're not replaying your to-do list at 2 a.m.You'll also hear how better sleep accelerates muscle recovery, reduces injury risk, and improves decision‑making and reaction time, giving you an edge in training, career, and life. We link the science to real‑world habits you can use tonight—no magic supplements required. By the end of this episode, you'll have a clear, simple plan for how to improve sleep quality, boost recovery, and calm your mind so you can wake up more energized, more grounded, and more dangerous—in all the right ways.Buy Robert's book here - https://www.amazon.com/62Romeo-SLEEP101-Weeks-Sleep-Restoration/dp/B0F8MLZQM2Feeling stuck? If you need help getting out of your rut, Will can help - head to willnotfear.com to learn more about his coaching to get you off the hamster wheel. More from MTM at: https://mentalkingmindfulness.com/Chapters:00:00 - Introductions02:50 - Rob Sweetman on Improving Sleep12:19 - Sleep Hygiene and Mental Health26:31 - How Light and Sound Affect Sleep29:06 - Light, Sound, and Sleep Quality32:29 - Brown Noise for Better Rest33:50 - Noise, Temperature, and Sleep37:50 - Building Consistent Sleep Routines40:00 - New Sleep Solutions for the Military41:58 - Developing Military Sleep Pods43:37 - Better Sleep Tools for Warfighters48:45 - Coaching High Performers on Sleep52:02 - Common Sleep Disruptors53:26 - Healthy Sleep Habits58:11 - Sleep Tracking: Pros and Cons01:01:06 - Why Deep Sleep and REM Matter01:02:36 - How Meal Timing Affects Sleep01:05:02 - Processed Foods, Obesity, and Health01:07:27 - Intermittent Fasting Insights01:08:51 - Eating Habits That Support Sleep01:11:13 - Closing Thoughts and GiveawayHosted by Ausha. See ausha.co/privacy-policy for more information.

Dr. Emily Cooper, Mark Wright, and Andrea Taylor talk with Maria from Buffalo, a longtime listener who shares her lifelong journey with obesity, psoriatic arthritis, and binge eating—and how finally understanding the science of metabolism gave her hope. Maria describes early childhood weight gain, joint damage, and years of restrictive dieting and food shame, then explains how GLP‑1 therapy (Zepbound) plus mechanical eating helped her lose about 50 pounds while eating more food, more often, and with more joy. Dr. Cooper breaks down the underlying biology—leptin, weight set point, the melanocortin pathway, and the impact of pain, sleep, and chronic inflammation on hunger hormones—and reframes obesity as a symptom of deeper metabolic problems, not a character flaw. This episode doubles as a practical, emotionally honest guide for patients trying to navigate a traditional health‑care system without a dedicated metabolic specialist.Key Questions AnsweredHow can rapid childhood weight gain, autoimmune disease, and early joint damage signal serious metabolic dysfunction rather than “too much food” or “not enough exercise”?What is leptin, what does “too low for your size” mean, and how does that affect hunger, weight set point, and weight loss?What is monogenic obesity testing, who might qualify for free genetic screening, and how can results inform (but not necessarily change) treatment?How do GLP‑1 medications like Zepbound work with mechanical eating so someone can lose weight while eating more regularly and with more variety?Which labs (fasting glucose, insulin, leptin, etc.) help uncover hidden metabolic issues, and when is a mixed‑meal test more useful than a simple fasting snapshot?When should brain‑active medications (such as bupropion/naltrexone combinations) be considered, and what trade‑offs and side effects matter?How can patients respectfully push for tests, challenge old “eat less, move more” advice, and set boundaries around weigh‑ins and stigmatizing language?Key TakeawaysIt's not your fault: Rapid childhood weight gain and early‑onset obesity often reflect serious metabolic biology, including rare gene variants, growth phases, and hormone signaling—not gluttony or laziness.Obesity is a symptom: Excess weight is better understood as a side effect of underlying metabolic fires (leptin issues, insulin resistance, brain signaling problems) that need proper diagnosis and treatment.Leptin really matters: Low leptin for your size can act as a biological brake on weight loss, and chronic dieting, under‑fueling, over‑exercise, and some high‑dose supplements can suppress it further.GLP‑1s plus mechanical eating: Medications like Zepbound can quiet food noise and support weight loss, but scheduled, balanced eating is essential to avoid under‑fueling, protect muscle, and support hormones.Pain and sleep are metabolic: Chronic pain and poor sleep increase hunger hormones like ghrelin and disrupt repair processes, worsening metabolic dysfunction unless directly addressed.Script your visits: Bring a printed list of diagnoses, medications, and questions; use patient portals to request specific tests; and practice simple boundary phrases around weighing and diet talk.Notable Quote“This isn't all just caused by diets and things like that. There was an original metabolic problem. It was amplified because of the food restriction and the psychology around it, but you are a product of cumulative insults to your system—not a moral failure.” — Dr. Emily CooperLinks & ResourcesPodcast Home: https://fatsciencepodcast.com/Cooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/Resources and education from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Show Question: questions@fatsciencepodcast.comDr. Cooper direct show email: dr.c@fatsciencepodcast.comFat Science is informational only and does not constitute medical advice.

Obesity and chronic kidney disease (CKD) are deeply interconnected as each condition increases the risk and severity of the other. In part 1 of this episode, our interprofessional panel of experts explores the science behind this bidirectional relationship and the epidemiologic data underscoring their connection. Listeners will gain insight into the underlying pathophysiology, including the roles of inflammation, altered kidney hemodynamics, and lipotoxicity. Through practical discussion and dissection of the literature, this episode highlights the importance of recognizing obesity as both a cause and consequence of CKD, and the crucial role nephrology professionals play in interrupting this cycle early. Please be sure to visit the National Kidney Foundation's Obesity in the Nephrology Clinic page for additional information and access to an infographic designed to support clinical care for managing obesity in individuals living with CKD: https://www.kidney.org/professionals/tools/obesity-nephrology-clinic Supported by Novo Nordisk

Effective management of obesity in patients with CKD requires a holistic, interprofessional approach. In part 2 of this episode, the conversation continues with translating the evolving evidence into practical guidance for nephrology teams. Experts review the importance of a person-centered approach integrating lifestyle interventions, pharmacologic therapies, and surgical options with a focus on safety, efficacy, and kidney-related outcomes. The discussion emphasizes how members of the nephrology care team can collaborate to personalize treatment, address appetite and nutrition concerns, and help patients achieve meaningful weight loss without compromising kidney health. Tune in for actionable insights and strategies to translate emerging science into individualized, kidney-friendly, weight management strategies. Please be sure to visit the National Kidney Foundation's Obesity in the Nephrology Clinic page for additional information and access to an infographic designed to support clinical care for managing obesity in individuals living with CKD: https://www.kidney.org/professionals/tools/obesity-nephrology-clinic Supported by Novo Nordisk

Medicare will get a 71% discount off the list price of Ozempic and Wegovy starting in 2027. That will bring the monthly costs of those drugs down from nearly $1,000 to $274. The Centers for Medicare and Medicaid Services also announced price reductions for 14 other drugs. We'll hear more. Plus, can a market economy that uses fake cash help food banks get the food donations they want?

Russia's long-standing requests are predominant in a peace deal for Ukraine brokered by American and Russian envoys. Rep. Marjorie Taylor Green, R-Ga., says she will resign her Congressional seat in January. Pill versions of the obesity drugs now requiring injections are on the way. BONUS: 2025's best plot-driven books.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy